Skip to main content

Table 3 Clinical information of patients who were unheard follow upinpublic health facilities of Addis Ababa, during 2007-June 2012

From: Effectiveness of isoniazid preventative therapy in reducing incidence of active tuberculosis among people living with HIV/AIDS in public health facilities of Addis Ababa, Ethiopia: a historical cohort study

Clinical information when ART initiated (N = 2046)

IPT exposed

N (%)

IPT Non-exposed

N (%)

N (%)

Chi-square

P value

WHO stage of HIV/AIDS

 Stage 1

151(16.02)

138(12.5)

289(14.1)

0.000

 Stage 2

367(39)

294(26.6)

661(32.3)

 

 Stage 3

394 (41.8)

551(49.9)

945(46.2)

 

 Stage 4

30 (3.18)

121(11.0)

151(7.4)

 

CD4cells count/μl(mean = 151.2, SD = 84.9)

 ≤200

537 (37.9)

1020(92.4)

1557(76.1)

0.000

 >200

263 (27.9)

226(20.5)

489(23.9)

 

Weight in Kg (mean = 53.2, SD = 9.5)

 <50

241(25.6)

506(45.8)

747(36.5)

0.011

 50–59

479(44.2)

366(33.1)

845(41.3)

 

 60–69

164 (17.4)

164(14.9)

328(16.0)

 

 >69

58 (6.2)

68(6.2)

126(6.2)

 

TB screened

 Yes

942(100)

1100(99.6)

2042(99.8)

0.64

 No

0

4(0.4)

4(0.2)

 

CPT adherence

 Good

791(84)

1096(99.3)

2032(99.6)

0.046

 Fair

3(.32)

6(0.5)

9(0.3)

 

 Poor

3(.32)

2(0.2)

5(0.2)

 

ART adherence

 Good

937(99.5)

1100(99.6)

2037(99.6)

0.124

 Fair

5(0.53)

2(0.2)

7(0.3)

 

 Poor

0

2(0.2)

2(0.1)

 

OIs after ART initiated

 None

937(99.5)

1052(95.3)

1989(97.21)

0.000

 Fungal

3(.32)

20(1.8)

23(1.12)

 

 Viral

0

12(1.0)

12(0.5)

 

 Bacterial

0

12(1.0)

14(0.7)

 

 Bacterial & fungal

0

4(0.4)

4(0.2)

 

 Othersa

0

4(0.4)

4(0.2)

 
  1. aProtozoal, viral & bacterial & fungal & viral infections